Kintor Pharmaceutical Limited (9939.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$1.41 (-1.05%) as of
Key statistics
- Market cap
- 689.35M
- Forward P/E
- -0.59
- EPS (TTM)
- -0.450
- Dividend yield
- 0.00%
- 52-week range
- 1.375 – 4.700
- Beta
- -0.68
- Revenue (TTM)
- 78.74M
- Profit margin
- -244.63%
- Volume
- 1.04M
About Kintor Pharmaceutical Limited
Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial. The company is also developing ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours that is in phase I and II clinical trial; GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer that is in phase I clinical trial; and GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC) that is in phase I clinical trial. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Suzhou, China
- Employees
- 122
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.